H

HLB Inc
KOSDAQ:028300

Watchlist Manager
HLB Inc
KOSDAQ:028300
Watchlist
Price: 75 400 KRW 2.86% Market Closed
Market Cap: 9.9T KRW
Have any thoughts about
HLB Inc?
Write Note

HLB Inc
Other Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

HLB Inc
Other Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
H
HLB Inc
KOSDAQ:028300
Other Liabilities
â‚©1.4B
CAGR 3-Years
32%
CAGR 5-Years
0%
CAGR 10-Years
10%
SD Biosensor Inc
KRX:137310
Other Liabilities
â‚©21.8B
CAGR 3-Years
413%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
B
BioPlus Co Ltd
KOSDAQ:099430
Other Liabilities
â‚©15B
CAGR 3-Years
599%
CAGR 5-Years
224%
CAGR 10-Years
N/A
T
T&L Co Ltd
KOSDAQ:340570
Other Liabilities
â‚©668.4m
CAGR 3-Years
12%
CAGR 5-Years
2%
CAGR 10-Years
N/A
H
Humasis Co Ltd
KOSDAQ:205470
Other Liabilities
â‚©95.4m
CAGR 3-Years
-14%
CAGR 5-Years
-58%
CAGR 10-Years
N/A
I
Interojo Co Ltd
KOSDAQ:119610
Other Liabilities
â‚©872.5m
CAGR 3-Years
-9%
CAGR 5-Years
-36%
CAGR 10-Years
19%
No Stocks Found

HLB Inc
Glance View

Market Cap
9.9T KRW
Industry
Health Care

HLB Inc. is a dynamic biopharmaceutical company dedicated to the discovery and development of innovative treatments for a range of serious diseases. Founded on the principles of scientific excellence and a commitment to patient care, HLB has quickly gained recognition for its robust portfolio of drug candidates targeting areas such as oncology, autoimmune diseases, and rare disorders. The company's strategic approach combines cutting-edge research with advanced clinical trials, leveraging partnerships with leading research institutions and healthcare organizations to propel its therapeutic innovations. With a strong financial backing and a clear vision for growth, HLB is not just about developing drugs; it’s about transforming patient outcomes and making a meaningful impact on global health. As an investor, HLB Inc. presents a compelling opportunity anchored in its core strengths: a seasoned management team with a proven track record, a rich pipeline of promising drug candidates, and a robust intellectual property portfolio that secures its market position. The company’s commitment to transparency and strategic operational decisions positions it well for sustainable growth in the competitive biopharmaceutical landscape. With the increasing demand for effective therapies and advancements in medical technology, HLB stands poised to unlock significant shareholder value while driving progress in medical treatment options. This compelling narrative of potential, combined with HLB's dedication to innovation, makes it an intriguing prospect for investors seeking exposure to the biopharmaceutical sector.

Intrinsic Value
880.61 KRW
Overvaluation 99%
Intrinsic Value
Price
H

See Also

What is HLB Inc's Other Liabilities?
Other Liabilities
1.4B KRW

Based on the financial report for Sep 30, 2024, HLB Inc's Other Liabilities amounts to 1.4B KRW.

What is HLB Inc's Other Liabilities growth rate?
Other Liabilities CAGR 10Y
10%

Over the last year, the Other Liabilities growth was 109%. The average annual Other Liabilities growth rates for HLB Inc have been 32% over the past three years , and 10% over the past ten years .

Back to Top